Trials / Completed
CompletedNCT02181764
A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Japan or Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KRN23 | Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2014-07-04
- Last updated
- 2017-03-03
Locations
2 sites across 2 countries: Japan, South Korea
Source: ClinicalTrials.gov record NCT02181764. Inclusion in this directory is not an endorsement.